FDA slaps stronger warnings on potent class of antibiotics

July 11, 2018

(HealthDay)—A powerful class of antibiotics will now come with stronger safety warnings about dangerous drops in blood sugar and neurological side effects that can include delirium and memory problems, the U.S. Food and Drug Administration said Tuesday.

Called fluoroquinolones, these drugs include levofloxacin (Levaquin), ciprofloxacin (Cipro), ciprofloxacin extended-release tablets, moxifloxacin (Avelox), ofloxacin, gemifloxacin (Factive) and delafloxacin (Baxdela). There are more than 60 generic versions of fluoroquinolones.

"The use of fluoroquinolones has a place in the treatment of serious bacterial infections—such as certain types of bacterial pneumonia—where the benefits of these drugs outweigh the risks," Dr. Edward Cox, director of the FDA's Office of Antimicrobial Products, said in an agency news release.

What kinds of infections should not be treated with these antibiotics?

According to the agency, the risks generally outweigh the benefits of fluoroquinolone treatment for patients with acute sinusitis, acute or chronic bronchitis and uncomplicated urinary tract infections.

Fluoroquinolones already carried warnings about a number of neurological side effects, but those warnings differed by .

Fluoroquinolone labels must now list the and all potential associated with this class of antibiotics—such as attention problems, disorientation, agitation, nervousness, memory impairment and delirium.

The FDA said the decision to require stronger safety warnings came after a review of reports of side effects it had received, as well as case reports published in medical journals.

Fluoroquinolones also carry warnings about disabling and potentially permanent side effects involving tendons, muscles, joints, nerves and the central nervous system.

Explore further: FDA bolsters warnings about class of antibiotics

More information: Consumer Reports has more on fluoroquinolones.

Related Stories

FDA bolsters warnings about class of antibiotics

July 26, 2016
(HealthDay)—The U.S. Food and Drug Administration announced Tuesday that it's strengthening label warnings on a class of antibiotics called fluoroquinolones because the drugs can lead to disabling side effects, including ...

FDA warns of potential side effects of powerful antibiotics

May 13, 2016
The U.S. Food and Drug Administration is ratcheting up its warning about the potential side effects of a type of commonly-prescribed powerful antibiotic often known by the brand name Cipro.

Risk of kidney disease doubled with use of fluoroquinolone antibiotics

June 3, 2013
The risk of acute kidney disease is doubled for people taking oral fluoroquinolone antibiotics, according to a study of published in CMAJ (Canadian Medical Association Journal).

Study examines risk of severe blood sugar swings among diabetics taking fluoroquinolones

August 15, 2013
Diabetic patients taking oral fluoroquinolones, a frequently prescribed class of antibiotics, were found to have a higher risk of severe blood sugar-related problems than diabetic patients taking other kinds of antibiotics, ...

Tuberculosis drug may work better than others in its class

August 17, 2017
Treatment of tuberculosis involves a combination of several drugs, sometimes including drugs from a class known as fluoroquinolones. Using computer simulations, scientists have shown that the fluoroquinolone known as moxifloxacin ...

Common antibiotics pose a rare risk of severe liver injury in older patients

August 13, 2012
The commonly used broad-spectrum antibiotics moxifloxacin and levofloxacin are associated with an increased risk of severe liver injury in older people, according to a new study published in CMAJ (Canadian Medical Association ...

Recommended for you

Researchers a step closer to understanding how deadly bird flu virus takes hold in humans

November 19, 2018
New research has taken a step towards understanding how highly pathogenic influenza viruses such as deadly bird flu infect humans.

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.